Cellectar Biosciences Expands Global Intellectual Property Estate

Core Insights - Cellectar Biosciences, Inc. has expanded its global intellectual property estate, securing new patents across Europe, Asia-Pacific, the Middle East, and the Americas, which strengthens its protection around iopofosine I 131 and its broader portfolio [1][2] Group 1: Intellectual Property Expansion - The newly issued patents cover critical therapeutic and platform strategies, reinforcing the uniqueness of the company's technology [2] - The expansion of the IP estate is seen as essential for the company's long-term commercial strategy and supports its commitment to providing new therapeutic options for patients with limited treatment choices [2] Group 2: Product Pipeline - The company's product pipeline includes iopofosine I 131, designed for targeted delivery of iodine-131, and CLR 125, an iodine-125 Auger-emitting program for treating triple negative breast cancer [4] - iopofosine I 131 has been studied in Phase 2b trials for multiple myeloma and CNS lymphoma, and is eligible for a Pediatric Review Voucher from the FDA upon approval [5] Group 3: Regulatory Designations - iopofosine I 131 has received multiple designations from the FDA, including Breakthrough Therapy, six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations for various cancer indications [5]